William Blair Weighs in on Nevro Corp.’s Q1 2025 Earnings (NYSE:NVRO)

Nevro Corp. (NYSE:NVRO) – Research analysts at William Blair issued their Q1 2025 earnings per share (EPS) estimates for shares of Nevro in a research note issued to investors on Tuesday, May 7th. William Blair analyst B. Vazquez expects that the medical equipment provider will post earnings per share of ($0.92) for the quarter. The consensus estimate for Nevro’s current full-year earnings is ($2.54) per share. William Blair also issued estimates for Nevro’s Q4 2025 earnings at ($0.34) EPS.

Nevro (NYSE:NVRO) last issued its quarterly earnings data on Tuesday, May 7th. The medical equipment provider reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.32. Nevro had a negative net margin of 21.69% and a negative return on equity of 30.22%. The firm had revenue of $101.90 million for the quarter, compared to analyst estimates of $97.90 million. During the same quarter in the prior year, the firm earned ($0.98) EPS. The company’s revenue was up 5.8% on a year-over-year basis.

A number of other research analysts have also commented on NVRO. Wells Fargo & Company decreased their price objective on Nevro from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Wednesday. Citigroup decreased their price target on Nevro from $18.00 to $16.00 and set a “neutral” rating on the stock in a report on Wednesday, April 3rd. Robert W. Baird dropped their price objective on Nevro from $23.00 to $19.00 and set a “neutral” rating for the company in a report on Thursday, February 22nd. Canaccord Genuity Group reduced their target price on shares of Nevro from $17.00 to $11.00 and set a “hold” rating on the stock in a research note on Wednesday. Finally, Piper Sandler dropped their price target on shares of Nevro from $15.00 to $12.00 and set an “underweight” rating for the company in a research note on Wednesday. One research analyst has rated the stock with a sell rating, twelve have given a hold rating and one has given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $20.00.

Nevro Price Performance

NVRO opened at $10.52 on Thursday. The company has a debt-to-equity ratio of 0.72, a current ratio of 6.37 and a quick ratio of 4.94. The company’s 50 day simple moving average is $13.04 and its 200-day simple moving average is $16.19. Nevro has a one year low of $10.02 and a one year high of $28.89. The stock has a market capitalization of $385.88 million, a P/E ratio of -4.09 and a beta of 0.96.

Hedge Funds Weigh In On Nevro

Several institutional investors and hedge funds have recently made changes to their positions in the company. Armistice Capital LLC raised its stake in Nevro by 46.7% during the 3rd quarter. Armistice Capital LLC now owns 3,456,000 shares of the medical equipment provider’s stock worth $66,424,000 after buying an additional 1,100,000 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Nevro by 69.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,048,026 shares of the medical equipment provider’s stock worth $22,554,000 after purchasing an additional 431,136 shares during the period. UBS Group AG lifted its holdings in shares of Nevro by 19,354.5% during the 3rd quarter. UBS Group AG now owns 903,272 shares of the medical equipment provider’s stock valued at $17,361,000 after purchasing an additional 898,629 shares in the last quarter. Principal Financial Group Inc. increased its stake in Nevro by 0.4% during the 4th quarter. Principal Financial Group Inc. now owns 720,529 shares of the medical equipment provider’s stock worth $15,506,000 after purchasing an additional 3,086 shares in the last quarter. Finally, Federated Hermes Inc. raised its holdings in Nevro by 380.1% during the 4th quarter. Federated Hermes Inc. now owns 431,153 shares of the medical equipment provider’s stock worth $9,278,000 after buying an additional 341,343 shares during the period. Institutional investors and hedge funds own 95.52% of the company’s stock.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.